Oncology Letters, 2014, 8(6):2806-2810.

Genistein enhances the effect of cisplatin on the inhibition of non‑small cell lung cancer A549 cell growth in vitro and in vivo

Dezhi Liu, Ling Yan, Lan Wang, et al

Department of Radiation Oncology, The Tumor Hospital of Jilin Province, Changchun, Jilin 130012, P.R. China

Correspondence to: Dr Changbin Yang, Department of Radiation Oncology, The Tumor Hospital of Jilin Province, 1018 Huguang Road, Chaoyang, Changchun, Jilin 130012, P.R. China

Although cisplatin (DDP) has been reported to be a promising antitumor therapy for non-small cell lung cancer (NSCLC), the effectiveness of the treatment remains limited due to an inherent tumor resistance to DDP. Genistein (GEN) is an abundant, naturally occurring isoflavonoid found in soy products that has been demonstrated to increase the anti-neoplastic activity of certain chemotherapy drugs in multiple tumor types. In the present study, DDP in combination with GEN was selected as a potential treatment to suppress tumor growth and simultaneously reduce the doses of the two drugs required for the treatment of NSCLC. Cell growth inhibition, apoptosis, cell cycle distribution and receptor signaling assays were conducted. In the in vivo study, DDP and GEN, either alone or in combination, were used to treat a xenograft model of the A549 cells. It was found that the combination of low concentrations of DDP and GEN induced significantly greater growth inhibition (P<0.01) and increased apoptosis in the A549 cells compared with either agent alone. In addition, DDP in combination with GEN could significantly suppress tumor growth in vivo compared with either agent alone. Combination treatment significantly suppresses constitutive phosphorylation of AKT and phosphoinositide-3 kinase, which may contribute to the inhibition of tumor growth. Overall, the present data suggested that GEN can increase the anti-neoplastic activity of DDP and that a combination of GEN and DDP is a potential drug candidate for the treatment of NSCLC.

希腊《肿瘤学快讯》，2014年

金雀异黄素在体内和体外可以增强顺铂对非小细胞肺癌 A549 细胞生长的抑制作用

刘德智，燕玲，王兰，等

中国吉林省长春市吉林省肿瘤专科医院放射肿瘤学

虽然顺铂 (DDP) 被报道对于非小细胞肺癌 (NSCLC)是一种有前途的抗肿瘤疗法，但是由于固有的肿瘤对顺铂的耐药性治疗效果仍然有限。金雀异黄素 （GEN） 是一种在大豆中发现的丰富，天然生成的异黄酮，已经被证实可以提高某些化疗药物对多种类型肿瘤的抗肿瘤活性。在本研究中，DD P与GEN联合应用被选为一种潜在的治疗方法，以抑制肿瘤的生长，同时降低治疗NSCLC所需两种药物的剂量。对细胞生长抑制、 细胞凋亡、 细胞周期分布和受体信号转导进行了检测。在体内研究中，DDP 和GEN，单独或者联合，被用于治疗 A549 细胞的异种移植模型。我们发现低浓度的 DDP 和GEN的联合诱导了明显更大的生长抑制作用 (P < 0.01) 并且提高了A549 细胞的凋亡与单独药物相比。此外，DDP 联合GEN能明显抑制体内肿瘤生长与单独药物相比。联合治疗显著抑制AKT成分和磷脂酰肌醇-3 激酶的磷酸化，可能有助于抑制肿瘤生长。总之，目前的数据表明 GEN 可以提高顺铂的抗肿瘤活性，并且GEN和 DDP 的联合是一种治疗非小细胞肺癌的潜在候选药物。